Simplified dermatological Amivantamab strategy; lazertinib 1 cycle lead in lazer then fortnightly Amivantamab….. this seems to be they way to go; interestingly UK cancer drugs fund allows starting 1cycle of lazer first. #ESMO26
21 views · 1 like · 0 reposts · 0 replies
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
https://esmocongress.esmo.orgSource: Dr Riyaz Shah · x.com